Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07432633 · ClinicalTrials.gov registry record · Phase 1

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

A Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Blue Earth Diagnostics.

Recruiting
Registry status
Phase 1
Development phase
71
Enrollment target
1
Study location

NCT07432633: Recruiting Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Blue Earth Diagnostics.

NCT07432633 is a Phase 1 study of Colorectal Cancer and Gastric Cancer that is actively recruiting participants, run by Blue Earth Diagnostics. The registered enrollment target is 71 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07432633, a Phase 1 study of Colorectal Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Blue Earth Diagnostics.

RECRUITING
Registry status
Phase 1
Development phase
71 participants
Enrollment target
1
Study location

Study Summary

This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Primary Outcome

Whole body effective dose of a single dose of \[18F\]FPyQCP

Interventions

  • DRUG [18F]FPyQCP

Study Locations (1)

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2026-01-31
Est. Completion 2028-01-31
Phase Phase 1
Blue Earth Diagnostics

9 total trials

What NCT07432633 shows while recruiting

NCT07432633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (95% lower).

The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which [18F]FPyQCP is the first listed.

NCT07432633 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07432633 about?

NCT07432633 is a clinical study titled "[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications". This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast ca...

What is the current status of trial NCT07432633?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2026-01-31. Estimated completion is 2028-01-31.

What conditions does trial NCT07432633 study?

This clinical trial studies the following conditions: Colorectal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Epithelial Ovarian Cancer, Invasive Lobular Breast Carcinoma.

What interventions are being tested in trial NCT07432633?

The interventions under investigation include: [18F]FPyQCP (DRUG).

Who is sponsoring clinical trial NCT07432633?

This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07432633 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07432633's enrollment target sits among peer trials

71 242nd of 381 higher than 139 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05452889 · 71 participants · Early Phase 1

    PET Image in PAH Patients

  • NCT05766943 · 71 participants · NA

    Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

  • NCT06229678 · 71 participants · Early Phase 1

    Ketones, SGLT2, HFrEF

  • NCT06377566 · 71 participants · Phase 2

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07432633, the US trial registry maintained by the National Library of Medicine. NCT07432633 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.